Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 14 Best Small Cap Stocks to Buy Right Now. On August 25, Raymond James increased the price target on Dyne Therapeutics, Inc. (NASDAQ:DYN) stock from $31 to $35, maintaining its Buy rating.

Martin Auster from Raymond James upgraded the price target on DYN as he remains optimistic on the upcoming DYNE-251 registrational cohort readout expected in late 2025. Auster sees potential in the upcoming investigational exon-skipping therapy for Duchenne Muscular Dystrophy (DMD). The company expects a Biologics License Application (BLA) filing in early 2026. The analyst’s confidence is based on three major factors, including the differentiated profile of DYNE-251 compared to Exondys 51, a competing therapy in the DMD treatment space.

Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating

On August 4, Dyne Therapeutics announced the FDA approval for the treatment of patients with DMD. Auster believes in a pathway to accelerated approval for the therapy, which could boost its market entry if successful in clinical trials.

“This Breakthrough Therapy Designation for DYNE-251 is a testament to its potential as a next-generation therapy designed to bring meaningful functional improvement to individuals with DMD for whom exon 51 skipping can lead to the production of near full-length dystrophin,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne Therapeutics.

As of September 5, Dyne Therapeutics, Inc.’s (NASDAQ:DYN) average price target of $38, based on analysts’ estimates, implies an upside of nearly 167.23% from current levels.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage neuromuscular disease company that focuses on discovering and developing therapeutics for neuromuscular diseases.

While we acknowledge the potential of DYN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DYN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.